Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Applied Dna Scns (APDN)

Applied Dna Scns (APDN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,230
  • Shares Outstanding, K 1,200
  • Annual Sales, $ 3,900 K
  • Annual Income, $ -11,690 K
  • 60-Month Beta 0.16
  • Price/Sales 0.89
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +768,561.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.20 +4.76%
on 11/11/19
10.40 -57.69%
on 10/25/19
-3.76 (-46.08%)
since 10/11/19
3-Month
4.20 +4.76%
on 11/11/19
17.60 -75.00%
on 09/18/19
-6.75 (-60.53%)
since 08/09/19
52-Week
4.20 +4.76%
on 11/11/19
49.56 -91.12%
on 11/19/18
-41.60 (-90.43%)
since 11/09/18

Most Recent Stories

More News
Applied DNA Sciences Announces Appointment of Scott L. Anchin to Board of Directors

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions and nucleic...

APDN : 4.40 (-15.22%)
Applied DNA Sciences Announces 1-For-40 Reverse Stock Split

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced...

APDN : 4.40 (-15.22%)
Applied DNA Receives Notice of Allowance on Patent Protecting its CertainT(R) Platform in Cellulosic Fibers and Materials

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced...

APDN : 4.40 (-15.22%)
Applied DNA Partners with Molecular Isotope Technologies to Elevate CertainT(R) for Brand Assurance and Provenance

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA", the "Company"), a leader in polymerase chain reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced...

APDN : 4.40 (-15.22%)
Molecular Tagging of Pharmaceutical Excipients Utilizing Applied DNA's Technology Published in Peer-Reviewed Journal

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA"), a leader in large-scale PCR-based DNA manufacturing, announced today that a scientific paper entitled, 'Anti-counterfeiting DNA molecular tagging...

APDN : 4.40 (-15.22%)
Applied DNA Receives Extension from Nasdaq

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA") ("we," "us," "our," the "Company"), a leader in large-scale PCR-based DNA manufacturing, today announced that the Nasdaq Hearings Panel (the "Panel"),...

APDN : 4.40 (-15.22%)
LineaRx's iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial

LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform...

TYME : 1.19 (-0.83%)
APDN : 4.40 (-15.22%)
Applied DNA Receives $1 Million Order to Supply SigNature(R) T Molecular Taggant for 2019-2020 Cotton Harvest Season

Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA", the "Company"), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today that it received a...

APDN : 4.40 (-15.22%)
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA"), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. ("LineaRx"), its majority-owned subsidiary focused on next-generation...

APDN : 4.40 (-15.22%)
Applied DNA Extends Textiles Business to Include Global Down and Feather Supply Chain in Partnership with Industry Leader Navarpluma

Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA", the "Company"), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today a sales and marketing...

APDN : 4.40 (-15.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade APDN with:

Business Summary

Applied DNA Sciences, Inc. provides proprietary DNA-embedded biotechnology security solutions, using non-human DNA, that verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion. They develop, market,...

See More

Key Turning Points

2nd Resistance Point 5.47
1st Resistance Point 4.93
Last Price 4.40
1st Support Level 4.03
2nd Support Level 3.67

See More

52-Week High 49.56
Fibonacci 61.8% 32.23
Fibonacci 50% 26.88
Fibonacci 38.2% 21.53
Last Price 4.40
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar